Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Eucrisa Generic Name & Formulations
Legal Class
Rx
General Description
Crisaborole 2%; oint.
Pharmacological Class
Phosphodiesterase 4 (PDE4) inhibitor.
How Supplied
Oint—60g, 100g
Manufacturer
Generic Availability
NO
Mechanism of Action
Crisaborole inhibits phosphodiesterase 4 (PDE-4), resulting in increased intracellular cyclic adenosine monophosphate (cAMP) levels. However, the exact mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
Eucrisa Indications
Indications
Mild to moderate atopic dermatitis.
Eucrisa Dosage and Administration
Adults and Children
<3mos: not established. ≥3mos: apply a thin layer twice daily to affected areas; may consider reducing to once daily after clinical effect is achieved.
Eucrisa Contraindications
Not Applicable
Eucrisa Boxed Warnings
Not Applicable
Eucrisa Warnings/Precautions
Warnings/Precautions
Not for ophthalmic, oral, intravaginal use. Discontinue immediately if hypersensitivity occurs. Pregnancy. Nursing mothers.
Eucrisa Pharmacokinetics
Absorption
Mean ± SD maximum plasma concentration (Cmax) and area under the concentration time curve post dose (AUC0-12) on Day 8 were 127 ± 196 ng/mL and 949 ± 1240 ng h/mL, respectively.
Systemic concentrations of crisaborole were at steady state by Day 8.
Distribution
Plasma protein bound: 97%.
Elimination
Renal.
Eucrisa Interactions
Not Applicable
Eucrisa Adverse Reactions
Adverse Reactions
Application site pain (eg, burning, stinging); hypersensitivity reactions, contact urticaria.
Eucrisa Clinical Trials
See Literature
Eucrisa Note
Not Applicable
Eucrisa Patient Counseling
See Literature
Images
